South Korean researchers from KAIST and Neogenlogic have developed an AI model to create personalized cancer vaccines. The AI identifies unique neoantigens in patients to train their immune systems and prevent recurrence. This new platform predicts neoantigens that trigger a robust B cell response, crucial for long-term antitumor immunity, marking a significant advancement in cancer vaccine design by incorporating B cell responses alongside T cell activation.